Medication diaries do not improve outcomes with highly active antiretroviral therapy in Kenyan children: a randomized clinical trial

Table 3 Outcomes compared between randomization arms adjusted for baseline CD4 percentage and caregiver antiretroviral drug use

Outcome variable	Diary arm		Control		P-value
	Mean or No*	SD or %**	Mean or No	SD or %**
No missed doses 3-day recall (questionnaire)	270*	85**	283*	92**	0.08^a
Adherence >95%	35/47	74	38/43	88	0.20
Mortality	9/53	17	7/46	15	0.67
Hospitalization	13/53	25	10/46	22	0.51
Mean CD4 cells/μl
6 months^b	585	92	664	105	0.25
15 months^b	729	95	689	88	0.83
Mean CD4 percent
6 months^b	17.2	3.4	16.3	1.6	0.92
15 months^b	17.6	1.6	18.9	2.0	0.36
Mean HIV-1 RNA log₁₀ copies/ml
3 months (n = 51)	2.69	1.52	2.43	1.17	0.57
6 months (n = 44)	2.27	1.72	2.14	0.94	0.33
9 months (n = 28)	2.77	1.40	2.40	1.27	0.24
VL <100 copies/ml
3 months	9/27	33	6/24	25	0.61
6 months	10/22	45	11/22	50	0.57
9 months	7/14	50	5/14	36	0.83
Mean WAZ^c
3 months (n = 67)	-2.14	0.28	-1.98	0.21	0.99
9 months (n = 62)	-1.36	0.33	-1.55	0.20	0.407
15 months (n = 58)	-1.25	0.23	-1.53	0.25	0.21
Mean HAZ^c
3 months (n = 62)	-2.60	0.26	-2.70	0.24	0.62
9 months (n = 61)	-3.73	1.64	-1.84	0.18	0.79
15 months (n = 57)	-1.76	0.25	-3.62	1.82	0.32
Mean WHZ score(SD)^c
3 months (n = 55)	-0.29	0.24	-0.68	0.24	0.18
9 months (n = 53)	-0.24	0.30	-0.35	0.25	0.88
15 months (n = 48)	0.21	0.20	-0.18	0.31	0.35
Loss to follow up	12*	23**	6*	13**	0.21

a: GEE (generalized estimating equation) used. b. Data from 20 and 24 children in diary and control respectively c. Numbers for all z-scores month 25 and 28 in diary and control respectively